National Science Foundation

The Wistar Institute is a leading independent biomedical research institution dedicated to advancing medical knowledge through innovative research and training. Established as the first of its kind in the United States, it has grown from an anatomical teaching museum into a prominent center for basic biomedical research. Designated as a National Cancer Institute Cancer Center in 1972, The Wistar Institute focuses on critical areas such as cancer, immunology, and infectious diseases. Its groundbreaking discoveries have contributed to the development of vaccines for diseases like rabies, rubella, and rotavirus, as well as the identification of genes related to breast, lung, and prostate cancer. The Institute promotes a collaborative research environment aimed at addressing some of the most pressing challenges in the biomedical field.

MelliCell is a biotechnology company focused on addressing chronic diseases through innovative tissue engineering technology that targets fat cells. The company’s platform enables the conversion of human stem cells into mature fat cells, facilitating their accelerated growth to sizes that surpass conventional limits. This technology aims to shrink fat cells and improve metabolic health, making it applicable for treating conditions such as obesity, diabetes, aging, oncology, and inflammation. MelliCell’s experienced team is developing oral small molecules that not only decrease fat mass but also reverse disease hallmarks while preserving lean mass. The efficacy of MelliCell’s technology has been recognized through various awards and partnerships with leading biopharmaceutical firms, highlighting its potential to enhance health outcomes and quality of life for individuals worldwide.

Prior authorization is a bureaucratic bottleneck that costs the US healthcare system an estimated $35 billion per year, much of which is administrative waste. At Epidaurus Health, we’ve built a patent-protected SaaS solution to fix this inefficiency. Amphitheater, our modular, AI-powered platform, enables Pharmacy Benefit Managers (PBMs) to process more prior authorizations faster, with higher clinical accuracy, and at a lower cost—without losing the human touch. Amphitheater addresses a clear pain point in the PBM midmarket – our customers are struggling to scale without spiraling operational expenses. Midmarket PBMs are also hungry for AI, but remain wary of solutions that could compromise their member experience. Epidaurus Health bridges that gap in a unique way: - AI + Pharmacogenomics (PGx): We are working to be the first SaaS in our space to integrate genomic data to reliably predict medication efficacy. - Patented Federated AI: Context-aware AI adapts to each PBM’s pre-existing workflows without data leakage—a critical industry requirement. - Radically Faster Onboarding: Unlike competitors requiring 4-6 months to curate rules-based clinical scenarios, our AI-driven intake engine fully digitizes guidelines in minutes to help support the human decision-making process with more precision. - Proven Cost Savings: Our solution cuts time and cost by up to 50%, reducing the need for PharmDs to manually review every case.

Transparent Path develops IoT-based logistics visibility technologies for perishable goods to reduce waste, cost, and risk in supply chains. It provides software and hardware that enable real-time location and condition monitoring through the Visibility Platform, using sensors to track shipments and alert partners when intervention is needed. The portfolio includes FreshScore, a predictive freshness algorithm, ProofScore, a data-transparency scoring system, and ProofTracker, a biodegradable sensor device. These tools support end-to-end visibility, improve decision making, and help buyers and sellers route the best products while reducing spoilage, waste, and disputes. The company serves food, pharmaceuticals, blood and plasma, transplant organs, and high-value hard goods, and works with consortiums to facilitate data sharing among supply chain partners. Strategic collaborations include Intel, T-Mobile, Duke University, and ReFED. Transparent Path has participated in accelerators and secured grants and angel investment to scale growth and feature development. The aim is to cut waste and environmental impact by keeping perishables out of landfills and strengthening trust across the supply chain.

Claria Medical specializes in developing innovative, minimally invasive surgical tools aimed at enhancing women's healthcare procedures. Their primary focus is improving hysterectomy and myomectomy surgeries by reducing tissue spread risk during laparoscopic procedures. Claria has received notable recognitions such as the 'Safer Technologies Designation' from the FDA and grants from the National Science Foundation and National Institute of Health.

Tiny Cargo specializes in the isolation and application of exosomes derived from bovine milk. Their technology enables industrial-scale production of these exosomes for various purposes, including pharmaceutical drug delivery, skin repair treatments, and nutritional applications.

QSimulate is a Boston-based company that specializes in developing cloud-based quantitative simulation tools focused on quantum molecular simulations. By leveraging the principles of quantum mechanics, QSimulate aims to address significant industrial-scale challenges primarily within the chemical and pharmaceutical sectors. Its innovative platform automates various workflows, allowing computational scientists to shift their focus from repetitive tasks to more strategic activities, ultimately enhancing productivity. This approach enables clients to accelerate their research and development processes, positioning QSimulate as a key player in advancing scientific inquiry and innovation in these industries.

Founded in Baltimore, Maryland in 2018, OncoSTING develops innovative therapies for bladder cancer. The company combines the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists to enhance immune response and improve safety profiles.

Brio provides strategic resourcing solutions to the biopharma, pharmaceutical, CRO, and medical device industries. They are skilled search experts with a passion for the science and art of recruiting, introducing only the best talent to preeminent companies.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Uniphage is a biotechnology company specializing in the development of safer and more efficient alternatives to traditional pesticides in plant agriculture. It leverages artificial intelligence and bacteriophages (viruses that infect bacteria) to predict and combat specific bacterial infections. The company's primary focus is on citrus greening, a devastating disease costing the U.S. over $2 billion annually. By employing AI algorithms, Uniphage accelerates the discovery of effective and safe bacterial viruses, aiming to reduce the use of harmful fungicides, bactericides, and antibiotics, thereby minimizing risks to human health and the environment.

Simmbion develops a revolutionary system that manufactures therapies within the human body, acting as a 'living pharmacy'. This innovative approach aims to overcome challenges associated with traditional drug delivery methods such as complex manufacturing processes, repeated injections, and high costs. By creating adaptable, reversible cell therapies resistant to supply chain disruptions, Simmbion strives to provide affordable and equitable healthcare solutions globally.

Cryptyx Bioscience is a biopharmaceutical company focused on discovering new therapeutic natural products from bacteria without the use of genetics or cloning. Their innovative platform aims to activate silent biosynthetic gene clusters within bacteria, allowing them to unlock the full potential of culturable microbes. By employing a bioactivity-first approach, Cryptyx seeks to rapidly identify new antibiotics and antiviral drugs, addressing critical needs in combating infectious diseases prioritized by health organizations. The company's technology is designed to provide a broad range of medical services and therapeutic applications, ultimately enhancing treatment options for patients.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

Stochastic Research Technologies is a software company specializing in providing research and innovative solutions for challenges within the chemical, pharmaceutical, and biomedical sectors. The company focuses on developing algorithms, methods, and tools that address complex issues related to energy and the environment, sustainability, molecular modeling, process management, and supply chain management. By leveraging advanced modeling and optimization techniques, Stochastic Research Technologies enables clients across various industries to effectively tackle biomedical problems and enhance their operational efficiencies. The company's commitment to applied research supports its mission to deliver practical and impactful solutions tailored to the needs of its diverse clientele.

Nostopharma specializes in treating pathologic bone growth to prevent rare bone diseases. Their nanoparticle drug delivery system aids patients in forming new bone following surgeries, burns, injuries, and other traumas, enabling healthcare providers to enhance clinical outcomes.

InvVax develops innovative vaccines using its proprietary platform. Its flagship product is a universal influenza vaccine designed to provide broad, long-lasting protection against all flu strains.

Isolere Bio, established in 2018, is a healthcare company specializing in biotherapeutic purification. Its core business involves simplifying and optimizing the manufacturing process of monoclonal antibodies and Adeno-Associated Viruses (AAVs) using Tangential Flow Filtration (TFF) technology. This streamlined approach aims to enhance global access to these vital drugs and research tools, while facilitating a seamless transition from laboratory-scale production to industrial-level output.

Auctus Biologics is a pre-clinical biotechnology company that develops antibody mimetic scaffolds for therapeutic and diagnostic applications. The company is engineering a ribose-binding protein to bind clinical targets with an affinity comparable to monoclonal antibodies while offering enhanced stability that allows survival in extreme environments, including repeated boiling cycles. This approach aims to address antibodies' liabilities, such as instability and costly cold-chain requirements, in order to enable advanced treatments and reduce overall treatment costs.

MBF Therapeutics, Inc. is a veterinary oncology company based in Ambler, Pennsylvania, focused on developing and commercializing innovative therapies for cancer treatment in dogs and cats. The company specializes in targeted immunotherapies and small molecule drugs that effectively disrupt tumor cell metabolism while preserving healthy cells and organs. Its product portfolio includes MBFT-101, a combination therapy for sarcomas and lymphoma, featuring a proprietary polyamine transport inhibitor and a potent inhibitor of ornithine decarboxylase, as well as MBFT-102, an immunotherapy based on the tumor suppressor/cytokine mda-7/IL24, which has shown promise in human cancers. Additionally, MBF Therapeutics employs a proprietary DNA vaccine platform and delivery system to develop immunotherapeutic vaccines aimed at enhancing protective immunity against infectious diseases in companion animals and livestock. The company maintains a strategic partnership with the Lankenau Institute for Medical Research to further advance its research and development initiatives.

Nasus Medical specializes in developing innovative, non-invasive drug-delivery devices aimed at improving the treatment of chronic sinusitis. Their flagship product enables patients to self-administer medication rapidly and conveniently, reducing the need for oral medications with systemic side effects, injections by healthcare professionals, or costly surgical procedures. This approach aims to enhance patient comfort, convenience, and outcomes while lowering overall healthcare costs.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Aracari Biosciences develops a vascularized micro-organ platform designed to accelerate drug discovery. This platform enables real-time imaging of vessel morphology, allowing for more authentic pre-clinical testing and enhancing decision-making in drug development.

Clairways specializes in smart lung monitoring for pharmaceutical clinical trials. Its wearable device captures key respiratory metrics for individuals with asthma, COPD, CF, or other chronic respiratory diseases.

Felix Biotechnology, Inc. is a San Francisco-based company founded in 2019 that specializes in developing biotherapeutics to combat microbial challenges in human health. The company focuses on creating treatments for antibiotic-resistant strains of bacteria and fungi, aiming to address the urgent need for effective management of infectious diseases. By accelerating the deployment of novel biotherapeutics, Felix Biotechnology seeks to provide healthcare professionals with precise and effective tools to tackle these pressing health issues.

Biochip Labs is a company based in Cleveland, Ohio, founded in 2019. It specializes in providing laboratory testing services focused on blood disorders, particularly sickle cell disease and thalassemia. The company offers a range of proprietary microfluidic biomarker assays, including tests for blood cell adhesion, red blood cell deformability, whole blood rheology, and endothelialized microfluidics. These assays are designed to evaluate the effectiveness of emerging targeted and curative therapies, allowing clinicians to monitor patients' responses to treatment accurately.

Niche Biomedical is a platform and therapy development firm that specializes in innovative treatments for chronic injuries and disorders that have not responded to conventional pharmacological methods. The company has developed the ExaStim, a non-invasive neuromodulation system designated as an FDA Breakthrough Device, aimed at treating spinal cord injuries. Additionally, Niche Biomedical is working on a gastrointestinal therapeutic device designed to alleviate postoperative ileus and restore gastrointestinal motility. This device leverages bioelectronic medicine to address diseases and injuries that are resistant to pharmaceutical therapies. The firm is also capable of creating miniaturized implantable devices with advanced functionalities, allowing for diverse electrode configurations to enhance treatment options through neuromodulation.

Kodikaz Therapeutic Solutions develops a genomic transfer delivery platform for RNA and DNA delivery vectors, aiming to move beyond conventional cancer therapies toward durable cures through targeted gene transfer. Its Zip-Code technology is a cell-specific delivery system derived from an endogenous human mechanism, designed to avoid the challenges of viral delivery and to be applicable across multiple cell types. The company translates cell-recognition and genomic integration mechanisms identified in human cancers into practical therapies, generating both in vitro and in vivo data in oncology to support the development of cell-targeted gene transfer technologies into curative treatments. Applications include cancers such as pancreatic cancer, multiple myeloma, and colorectal cancer, and the platform supports collaborations to help clients develop cell-specific gene transfer approaches.

Nano PharmaSolutions specializes in enhancing the bioavailability of insoluble drugs through its proprietary nanoformulation technology. The company has developed an innovative phase-transition technology platform that significantly improves the solubility of BCS 2 and BCS 4 active pharmaceutical ingredients (APIs) without the need for excipients, which are typically used in traditional processes like spray-dry dispersion and emulsification. By vaporizing the API and depositing it onto a carrier molecule, Nano PharmaSolutions enables the production of nanoparticles that can be processed into various dosage forms. Additionally, the company focuses on delivering neurodegenerative therapeutics directly to the brain via an intranasal route, facilitating a rapid onset of action and enhancing safety profiles. Their pipeline includes treatments for conditions such as Parkinson's disease, peripheral neuropathy, and substance abuse disorders, positioning Nano PharmaSolutions as a key player in the field of nanomedicine.

Ancilia Biosciences is a biotechnology company focused on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components of the gut microbiome. By concentrating on enhancing healthy gut bacteria and their predatory phages, Ancilia develops therapeutic strains that can effectively combat chronic diseases in the fields of immunology and oncology. Additionally, the company is pioneering a new class of live biotherapeutics that allow for the precise targeting of phages or viruses known to induce lysis, thereby advancing treatment options in microbiome-related health conditions.

HC Simulation, founded in 2011 and based in Canton, Mississippi, focuses on developing advanced products that utilize the HumMod engine to deliver high-quality simulations of human physiology. The company's offerings enable users to explore physiological interactions that may be difficult to observe in traditional settings. By providing a platform for realistic modeling, HC Simulation supports the ideation, development, and prediction processes for innovative medical devices and pharmaceuticals.

MedChem Partners is a medicinal chemistry CRO that specializes in developing small molecule therapeutics. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Founded in 2018, Paramita Therapeutics is a biotechnology company based in San Diego, California. It specializes in developing new therapeutics for cancer and infectious diseases.

Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative therapies for distressed neurological conditions and associated symptoms, including pruritus resulting from liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which enhances drug delivery by avoiding first-pass metabolism and significantly reducing glucuronide metabolites excreted by the kidneys. This technology aims to provide effective relief from various conditions, such as insomnia, anxiety, depression, and skin excoriation, thus offering improved efficacy and safety for patients. With a strong management team, an experienced advisory board, and a dedicated group of scientists and clinicians, Avior Bio is well-positioned to advance its mission of delivering high-value therapeutic solutions.

Verantos is the market leader in high-validity real-world evidence for life sciences. By incorporating robust clinical narrative data, artificial intelligence technology, and measured validity, Verantos is the first company to generate research-grade evidence at scale across all therapeutic areas. The Verantos Evidence Platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for market access, HEOR, medical affairs, and regulatory use.

Ballydel Technologies is a research and development company founded in 2018 and headquartered in Newark, Delaware. It focuses on creating innovative material and technology solutions aimed at various sectors, including space exploration, defense, public health, and societal applications. The company specializes in areas such as nanocomposite design and synthesis, hypersonic materials and manufacturing, as well as pharmaceutical tagging and authentication. By providing advanced materials and technologies, Ballydel Technologies enables clients to enhance existing products and optimize their manufacturing processes.

SpheroFill is a drug delivery platform that specializes in creating innovative injectable tissue fillers, specifically designed to address age-related atrophy in the larynx. Utilizing a unique combination of solid, hollow, and porous-wall hollow glass microspheres along with biocompatible and bioactive matrices, SpheroFill enhances drug delivery for healthcare professionals. Its technology enables improved patient compliance by reducing dosing frequency and allows for oral formulations that current technologies cannot achieve. By focusing on the protection, delivery, and controlled release of active pharmaceutical ingredients, SpheroFill represents a significant advancement in the field of drug administration.

Talus Bio is a biotechnology company specializing in drug discovery. It focuses on developing therapies targeting challenging cancer transcription factors using its proprietary MARMOT platform, which integrates functional proteomics, automated biology, machine learning, AI, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Infini Fluidics develops injectable drug delivery systems intended to treat diseases such as cancer and cardiovascular disease. They provide injectable drug delivery systems at an industrial scale on a portable chip, combining microfluidics with semiconductor technology, enabling patients, healthcare providers, and facilities to get access to lifesaving drugs.

Amberstone Biosciences is a biotechnology company focused on discovering novel immunotherapies aimed at addressing challenging medical targets that traditional methods struggle to tackle. The company utilizes its proprietary microfluidics-powered AmberFlow drug-discovery platform, which allows for the analysis of single-cell function within a customizable microenvironment. This innovative approach, combined with the expertise of its team in immuno-oncology and single-cell assay biology, positions Amberstone to develop transformative therapeutic antibodies that cater to patients with unmet medical needs. Through creative partnerships and advanced technologies, Amberstone Biosciences seeks to overcome conventional limitations in therapeutic development, ultimately enhancing patient care and outcomes.

Sunthetics accelerates pharmaceutical process development using electrochemical methods. Its smart reactors and machine-learning platform enable chemists to create lead molecules ten times faster, using less energy and reducing waste. While initially focused on pharma, Sunthetics' technology can be applied across chemical industries.

Seaspire Skincare specializes in developing multifunctional colorants and actives inspired by ocean biodiversity. Its flagship product, Xanthochrome, offers broader UV protection and aims to replace harmful ingredients in skincare products, promoting sustainability and reduced adverse effects on human and marine health.

New Horizon Biotech is a biotechnology company focused on enhancing the production of biopharmaceutical products through innovative technologies. The firm is concluding testing of its patented Single Use Horizontal Fermentor system (SUHF™), which is designed for single-use microbial fermentation. This system aims to provide significant production and operational cost savings while improving efficiency compared to traditional fermentor designs. By optimizing supply chains and ensuring consistent quality, New Horizon Biotech seeks to deliver high-value biopharmaceutical products, including antibiotics, vaccines, and therapeutic proteins, to a global market. The company’s advancements are positioned to enhance the competitive edge of its users within the biotechnology sector.

Quick-Med Technologies, Inc. is a life sciences company dedicated to developing and commercializing proprietary technologies aimed at infection prevention and control within the medical and consumer healthcare sectors. Founded in 1997 and headquartered in Gainesville, Florida, the company specializes in the research and development of biomedical products and devices with antibacterial applications. Its core technologies include NIMBUS, a family of advanced polymers with antimicrobial and hemostatic properties; Stay Fresh, a chemical formulation for textiles that provides durable antimicrobial protection; and MultiStat, a series of patented methods and compounds for skin therapy. Quick-Med serves a variety of clients, including government agencies and companies in healthcare, medical, apparel, textile, and personal care industries.

VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials. It develops disease-specific biosimulation models to simulate how a drug interacts in biological systems, supporting preclinical and clinical programs. Its BIOiSIM platform covers small molecules, large molecules, and viruses, using AI-driven biosystem simulations to inform drug design, optimize development timelines, and reduce animal testing. The company aims to accelerate drug development and enable more personalized healthcare.

Florica Therapeutics is a biotechnology company founded in 2019 and based in Livermore, California. The company specializes in the development of exosome-based therapeutics aimed at extending lifespan and preventing diseases associated with aging. Florica's innovative therapeutics focus on delivering drugs to the brain and provide alternatives for treatment of life-altering conditions such as leukemia and Tay-Sachs disease. By leveraging exosome technology, the company aims to offer health institutions access to novel treatments that enhance patient longevity and quality of life.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

iReprogram is a cell regeneration laboratory based in Ann Arbor, Michigan, established in 2017. The company focuses on advancing personalized medicine through innovative cell reprogramming technology. By utilizing a high-fidelity prototype computational tool, iReprogram generates transcription factor recipes that facilitate cellular trans-differentiation, particularly for cancer treatment. This technology aims to enhance the effectiveness of cancer therapies, ultimately allowing patients to benefit from more tailored and effective treatment options.

Founded in 2018, Souvie Biodelivery specializes in developing innovative drug delivery systems using engineered exosomes. Its platform aims to enhance biocompatibility, reduce immunogenicity, and improve specificity for targeted treatments across various diseases like immuno-inflammation, cancer, and neurological disorders.

Founded in 2018, GMJ Technologies specializes in developing microanalytical technologies for biopharmaceutical and biomedical applications. The company's core product is a proprietary analytical tool that combines capillary electrophoresis with an optical-mass spectrometry interface, offering fast, reliable protein analysis with high sensitivity and reduced sample consumption.

Akanocure Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative anti-cancer therapies aimed at treating various forms of cancer, particularly those that have metastasized. Recognizing that metastasis is responsible for the majority of cancer-related deaths, Akanocure focuses on creating novel small molecules that can block metastatic processes. The company's approach emphasizes the synthesis and development of bio-targeted chemotherapeutic agents derived from natural resources, which not only target cancer cells more effectively but also address the side effects associated with conventional chemotherapy. By leveraging the expertise of its team throughout the drug discovery and development process, Akanocure aims to enhance treatment outcomes and improve the quality of life for cancer patients.

Founded in 2016, Ernest Pharmaceuticals is a biotechnology company based in Hadley, Massachusetts. It specializes in developing cancer-killing bacteria using synthetic techniques to create motile, tumor-penetrating bacterial therapeutics for treating metastatic and inoperable tumors.

Ubiros specializes in producing electric soft grippers for automation in various industries. Their products, including Gentle Flex Module, Gentle Duo, and Gentle Pro, are designed to handle delicate and irregular items without requiring external air sources, reducing costs, complexity, and noise compared to traditional pneumatic or vacuum grippers.

TEGA Therapeutics develops glycoscience-based technologies to treat life-threatening diseases. It focuses on glycan science to enhance delivery of enzyme replacement therapies to the brain for lysosomal storage disorders and on producing recombinant heparan sulfate and heparin. The company aims to overcome the blood-brain barrier to enable treatments for unmet medical needs and is based in La Jolla, California.

Seven Biosciences provides drug discovery platforms for G-protein coupled receptors. The company, based in Davis, California, was founded by Grace Mizuno and Lin Tian.

Bondwell Technologies is a biotechnology company focused on developing biomaterial-based technologies that harness the natural capabilities of proteins and molecular tools. The company creates innovative materials with diverse structural, mechanical, and functional properties tailored for various applications. These applications include tissue engineering, biosensing, drug delivery, and photonics. By optimizing its technologies, Bondwell aims to facilitate advancements across multiple fields such as energy, environment, and medicine, thereby contributing to significant research and development efforts in these critical areas.

Claria Medical specializes in developing innovative, minimally invasive surgical tools aimed at enhancing women's healthcare procedures. Their primary focus is improving hysterectomy and myomectomy surgeries by reducing tissue spread risk during laparoscopic procedures. Claria has received notable recognitions such as the 'Safer Technologies Designation' from the FDA and grants from the National Science Foundation and National Institute of Health.

FruitVaccine is a company based in Champaign, Illinois, that specializes in the production of fruit-based vaccines aimed at providing immunity against widespread infectious diseases. Founded in 2017, the company focuses on developing noninvasive, orally administered vaccine alternatives. Its products come in various forms, including gummy-like pills, oral drops, and fruit purees, making them accessible and appealing. These vaccines are designed to be natural, vegan-friendly, and environmentally sustainable, distinguishing them from traditional injectable options. FruitVaccine's innovative approach aims to enhance immunization efforts by offering a more palatable and less invasive means of disease prevention.

Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. It employs cell engineering techniques to create customized vesicles aimed at advancing immuno-oncology and gene therapy. By leveraging a synthetic biology approach, Jupiter Therapeutics facilitates the rapid design and synthesis of a diverse pipeline of therapeutic assets that address critical areas such as cancer and autoimmunity. The company allows medical researchers to utilize insights from cell-membrane studies to enhance the effectiveness of CAR T-cells and bi-specific antibodies, thereby contributing to innovative treatments in the biotherapeutics field.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

VerImmune, based in Baltimore, Maryland, is an Immuno-Oncology company focused on developing innovative cancer therapies through its proprietary technology known as Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs). This first-in-class approach aims to harness and redirect pre-existing immune memory from pathogenic infections or childhood vaccines towards tumors. By doing so, VerImmune seeks to offer a transformative treatment option for patients with various types of cancers, especially those facing treatment resistance or limited therapeutic choices. The company's goal is to provide a low-toxicity solution that delivers durable benefits across a broad spectrum of cancer types.

Founded in 2010, VaxForm specializes in vaccine formulation development services. It supports clients from project definition to implementation, focusing on bacterial or viral antigen formulations, vaccine combinations, and live attenuated vaccines. The company also assists in regulatory compliance, patent preparation, and scientific publication writing.

StabiLux Biosciences specializes in the development of high-brightness fluorophores that enhance the capabilities of reagents used in flow cytometry. The company offers a drop-in platform technology that allows researchers to detect previously undetectable substances while maximizing the efficiency of existing equipment without requiring additional parts or new software. StabiLux's fluorophores are designed to be compatible with current flow cytometers, significantly improving brightness across the visible spectrum and minimizing noise distortion. This innovation enables users to feasibly detect targeted or cancer cells, thereby advancing research in various fields, including diagnostics and therapeutic development.

AgThera is a biotechnology company focused on discovering, developing, and commercializing a new class of antimicrobial medicines aimed at treating infectious diseases. The company specializes in advanced probiotics engineered to effectively eliminate pathogens, including antibiotic-resistant bacteria. AgThera's innovative platform utilizes probiotics that express and secrete antimicrobial peptides, which can aid in the development of drugs for both human and livestock applications. The company has received Small Business Innovative Research grants from the US National Science Foundation and the US Department of Agriculture to support its cutting-edge, AI-enabled research and development initiatives. Through its work, AgThera aims to address the growing challenge of antibiotic resistance in healthcare and agriculture.

Prime Labs is a technology company that offers cloud-based SaaS platforms for mass spectrometry data processing, analysis, reporting, and visualization in the field of medical drug discovery. Its software enables scientists to conduct experiments more efficiently, accurately, and comprehensively, streamlining workflows and reducing time spent on typically tedious processes. The platform is user-friendly and requires minimal training or installation, making it accessible to a wide range of users.

New Equilibrium Biosciences develops a platform that leverages artificial intelligence to learn biophysics, revealing opportunities for structure-based drug design.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Caza Health is a biotech company specializing in the microbiome, immunology, and oncology. The company was founded in 2019 and is headquartered in Earlysville, Virginia.

Intact Therapeutics designs and develops a thermosensitive, mucoadhesive drug-delivery platform for gastrointestinal disorders. The company focuses on smart gels that are liquid at room temperature and become mucoadhesive at body temperature, enabling localized drug concentrations with reduced systemic exposure. Its technology targets conditions such as ulcerative colitis and other GI diseases, aiming to provide effective, patient-friendly therapies with minimal discomfort. Founded in 2015 and based in Belmont, California, the company pursues formulations that improve retention and efficacy and offer a more comfortable healing experience.

VeraMorph is a pharmaceutical company established in 2017 and based in Mansfield, Massachusetts. The company specializes in developing an innovative oral drug delivery technology that utilizes proprietary oral hydrogel tablets. This technology aims to enhance drug stability, achieve a rapid dissolution rate, and maintain prolonged high saturation levels in oral dosage forms. VeraMorph's approach allows for higher drug loading compared to traditional formulations, enabling pharmaceutical companies to improve product performance while also reducing the cost and time required to bring their products to market. Through its focus on contract manufacturing and formulation services, VeraMorph seeks to advance the efficiency of drug delivery systems in the pharmaceutical industry.

Advaita Corporation, established in 2005 and based in Plymouth, Michigan, is a bioinformatics company that specializes in developing software tools for the research and pharmaceutical industries. The company's flagship product, Pathway-Guide, is a gene-expression analysis tool designed to assist biologists and drug researchers in interpreting complex data from gene-expression experiments. Additionally, Advaita offers consulting services that include pathway analysis, biological model building, biomarker identification, expression data interpretation, report creation, and training on data interpretation. The company's software helps investigators, core facilities, and enterprise bioinformatics teams analyze gene expression data, with capabilities to integrate multi-omic data from a systems biology perspective.

Kalion is an industrial biotechnology company focused on producing glucaric acid and S-3 hydroxybutyrolactone (3-HBL) from renewable feedstocks via traditional, green fermentation using microbes developed with proprietary synthetic biology techniques. Based in Milton, Massachusetts, the company targets chemicals for industrial, material, and pharmaceutical and nutraceutical applications, enabling customers to replace oil-based materials with purer, bio-based inputs. Kalion was established in 2010 and operates to scale sustainable fermentation processes that convert renewable resources into valuable specialty chemicals.

Proteios Technology develops products and services to support the discovery and scalable manufacturing of biopharmaceuticals. It offers protein purification kits, including gravity-based and spin kits, enabling safe and efficient purification with reduced environmental impact and lower costs. Founded in 2015 and headquartered in Issaquah, Washington.

Oscillo Biosciences is a company focused on developing innovative pharmacological treatments for Alzheimer's disease and related disorders. The firm combines a prescription medical device with digital therapeutic solutions aimed at restoring healthy brain function in individuals suffering from mild cognitive impairment and Alzheimer's disease. Their approach is rooted in the understanding that disruptions in brain rhythms affect memory and cognition in these patients. Additionally, Oscillo Biosciences creates human-centered technologies that rehabilitate patients with language, cognitive, and motor impairments by simulating the brain's synchronization to sounds and coordinating rhythmic behaviors like speech and movement. Through real-time perceptual analysis of music and various applications, their therapies offer a comprehensive method to enhance cognitive function and improve the quality of life for affected individuals.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Koliber Biosciences is a biotechnology company focused on leveraging machine learning and artificial intelligence to enhance biomedical research and drug development. It offers a synthetic biology research platform that emphasizes statistically-guided experimental design, advanced modeling, and data analytics. By providing predictive modeling and practical statistics coaching, Koliber Biosciences aims to accelerate the discovery of new pharmaceuticals, enabling pharmaceutical companies to streamline their research processes and bring innovative therapies to market more efficiently.

Inso Biosciences is an early-stage biotechnology company that develops microfluidic hardware platforms for genomic sample handling. The company's patented microfluidic technology enables high-efficiency processing of cellular material and the separation and isolation of cellular components, supporting genomic analysis and DNA sequencing workflows. Its platform aims to improve long-read DNA extraction, multiomic sample processing, and pathogen surveillance, enabling healthcare and biotech organizations to perform biological sample preparation with greater efficiency and accuracy.

Akanocure Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative anti-cancer therapies aimed at treating various forms of cancer, particularly those that have metastasized. Recognizing that metastasis is responsible for the majority of cancer-related deaths, Akanocure focuses on creating novel small molecules that can block metastatic processes. The company's approach emphasizes the synthesis and development of bio-targeted chemotherapeutic agents derived from natural resources, which not only target cancer cells more effectively but also address the side effects associated with conventional chemotherapy. By leveraging the expertise of its team throughout the drug discovery and development process, Akanocure aims to enhance treatment outcomes and improve the quality of life for cancer patients.

IDEM Systems provides drug testing kits and drug intelligence technology based on academic research. The testing system uses a novel chemical method to identify drugs, including heroin, other opiates, fentanyl and its derivatives, cocaine, and others. Among the devices are a handheld spectrometer, a sample pen, and a mobile application that allows users to access a proprietary database to identify suspect substances on-site accurately.

QCMedchain is a startup focused on revolutionizing the pharmaceutical supply chain through the use of blockchain technology. The company has developed a platform that allows for real-time tracking of medications at the package level, ensuring that each medicine can be traced from manufacturer to consumer. By generating, storing, and transferring metadata on a secure network, QCMedchain guarantees the authenticity of medicines, making the data immutable. This enables pharmaceutical companies and government entities to monitor the entire supply chain effectively, enhancing safety and transparency in the distribution of medical products. Through its innovative approach, QCMedchain aims to save lives and transform business practices within the industry.

Capienda Biotech is a biotechnology company focused on enhancing the drug discovery process by developing an innovative bioanalytical platform. This platform combines advanced instrumentation with assay chemistry, allowing for higher quality small molecule designs and significantly improving the efficacy of drug development. By providing crucial data that addresses a critical bottleneck in the industry, Capienda helps reduce the time and cost associated with bringing new medicines to market. Its high-throughput kinetics system offers a throughput 48 times greater than traditional methods, streamlining the process without requiring specialist scientists. The company generates recurring revenue through the sale of its laboratory instrument systems and assay chemicals, positioning itself as a key player in the biotechnology sector.

Niche Biomedical is a platform and therapy development firm that specializes in innovative treatments for chronic injuries and disorders that have not responded to conventional pharmacological methods. The company has developed the ExaStim, a non-invasive neuromodulation system designated as an FDA Breakthrough Device, aimed at treating spinal cord injuries. Additionally, Niche Biomedical is working on a gastrointestinal therapeutic device designed to alleviate postoperative ileus and restore gastrointestinal motility. This device leverages bioelectronic medicine to address diseases and injuries that are resistant to pharmaceutical therapies. The firm is also capable of creating miniaturized implantable devices with advanced functionalities, allowing for diverse electrode configurations to enhance treatment options through neuromodulation.

Inso Biosciences is an early-stage biotechnology company that develops microfluidic hardware platforms for genomic sample handling. The company's patented microfluidic technology enables high-efficiency processing of cellular material and the separation and isolation of cellular components, supporting genomic analysis and DNA sequencing workflows. Its platform aims to improve long-read DNA extraction, multiomic sample processing, and pathogen surveillance, enabling healthcare and biotech organizations to perform biological sample preparation with greater efficiency and accuracy.

VivoZ Biolabs specializes in developing cell culture platforms that replicate the complex 3D tumor microenvironment. The company's flagship technology is a patented layered microfluidic tissue assay, which serves as an ex vivo platform for drug screening, diagnosis, and personalized cancer treatment. This innovative microfluidic array mimics the dynamic conditions of tumor tissue, allowing for mid-to-high throughput maintenance of micro-tumor growth and functions. This capability enables healthcare professionals to predict and select candidate compounds more effectively during the drug discovery process.

IonDX is a bioanalytical instrumentation company specializing in advanced systems for analyzing biologic drugs. Founded by experts with over four decades of experience, the company's patented ion mobility technology enables high-throughput analysis of proteins and biotherapeutics.

Amberstone Biosciences is a biotechnology company focused on discovering novel immunotherapies aimed at addressing challenging medical targets that traditional methods struggle to tackle. The company utilizes its proprietary microfluidics-powered AmberFlow drug-discovery platform, which allows for the analysis of single-cell function within a customizable microenvironment. This innovative approach, combined with the expertise of its team in immuno-oncology and single-cell assay biology, positions Amberstone to develop transformative therapeutic antibodies that cater to patients with unmet medical needs. Through creative partnerships and advanced technologies, Amberstone Biosciences seeks to overcome conventional limitations in therapeutic development, ultimately enhancing patient care and outcomes.

Flaskworks is a company focused on enhancing the production of immunotherapeutics and dendritic cell-based vaccines. It develops innovative technologies for manufacturing dendritic cells and creates modular, closed, and disposable systems designed to overcome the challenges associated with therapy bottlenecks. By addressing these critical issues, Flaskworks aims to enable physicians to treat patients with greater success and efficiency, particularly in the context of cancer and other diseases.

Prime Labs is a technology company that offers cloud-based SaaS platforms for mass spectrometry data processing, analysis, reporting, and visualization in the field of medical drug discovery. Its software enables scientists to conduct experiments more efficiently, accurately, and comprehensively, streamlining workflows and reducing time spent on typically tedious processes. The platform is user-friendly and requires minimal training or installation, making it accessible to a wide range of users.

Bezoar Laboratories is focused on enhancing the health of humans, animals, and the environment through innovative microbial solutions. The company develops probiotic medical and pharmaceutical products designed to alleviate gastrointestinal issues, particularly those related to methane gas production. Its offerings are formulated to be free of gluten and dairy, while maintaining low acidity levels. This formulation aims to provide customers with relief from symptoms such as bloating, constipation, and diarrhea. Bezoar Laboratories is committed to creating effective solutions that promote overall well-being.

Sasya is a biotech company that produces functional supplements. Its products are applicable across all species including humans, companion animals, and fish.

EnTox Sciences is a manufacturer of analytical instruments, primarily serving the life science research and pharmaceutical industries. Their flagship product, the Barofuse, is designed to examine metabolic, signaling, and secretory activity in living tissue, helping clients enhance drug safety and reduce market risks.

Visikol Inc. is a New Jersey-based company specializing in advanced drug discovery through innovative bio-imaging and bioinformatics solutions. The company develops and provides cutting-edge tissue clearing technology and 3D imaging tools that enhance the visualization of plant and biological specimens. Its flagship product, Visikol, enables researchers to conduct optical sectioning of plant tissues, facilitating the identification of adulterants and the assessment of sample quality and authenticity. In addition, Visikol offers a range of tissue clearing kits and reagents, including Visikol HISTO, which seamlessly integrate 3D imaging into existing tissue processing workflows. The company's services include end-to-end drug discovery offerings, such as 2D and 3D cell culture model development, in vitro screening, and digital pathology, all aimed at transforming biological tissues into high-resolution images and quantitative data sets for informed decision-making in research and development.

Zebra Analytix, Inc. specializes in the development and commercialization of miniature gas chromatography systems utilizing microelectromechanical systems technology, which is exclusively licensed from Virginia Tech University. The company offers innovative products, including the Zebra-GC Model L and Modular Zebra-GC Model M, as well as micro pre-concentrators. Their solutions are designed for various applications, including quality control and safety in the food and beverage industry, environmental monitoring, and uses in the chemical, pharmaceutical, and energy sectors. Founded in 2017 and headquartered in Fayetteville, Arkansas, Zebra Analytix focuses on delivering portable, versatile, and efficient analytical tools that enable businesses to analyze volatile compounds with enhanced speed and precision. Additionally, the company provides services for column refurbishment and custom designs tailored to specific research needs.

Advaita Corporation, established in 2005 and based in Plymouth, Michigan, is a bioinformatics company that specializes in developing software tools for the research and pharmaceutical industries. The company's flagship product, Pathway-Guide, is a gene-expression analysis tool designed to assist biologists and drug researchers in interpreting complex data from gene-expression experiments. Additionally, Advaita offers consulting services that include pathway analysis, biological model building, biomarker identification, expression data interpretation, report creation, and training on data interpretation. The company's software helps investigators, core facilities, and enterprise bioinformatics teams analyze gene expression data, with capabilities to integrate multi-omic data from a systems biology perspective.

Abalone Bio, Inc. is a biotechnology company based in Richmond, California, founded in 2017. The company specializes in the development of antibody drugs aimed at treating a range of conditions, including pain, inflammatory diseases, rare cancers, and rare kidney diseases. Abalone Bio utilizes libraries of yeast cells that express various antibody variants to create recombinant protein versions of its antibodies. This innovative approach allows the company to effectively activate or inhibit drug targets, confirming their efficacy through human cell assays. By focusing on unlocking new disease treatments, particularly for peripheral neuropathy and other rare diseases, Abalone Bio aims to advance the field of medicine through the integration of gene sequencing and synthetic biology.

SpIntellx, Inc. is a computational and systems pathology company based in Pittsburgh, Pennsylvania, that specializes in spatial intelligence software products designed for analyzing pathology tissue sections in cancer diagnosis. Founded in 2017, the company offers innovative solutions such as SpIntellx, which processes image data sets from various imaging platforms and reagents, and HistoMapr, a computational guide for pathologists. Additionally, TumorMapr is utilized to analyze the spatial interactions of biomarkers within whole slide images using multiplexed fluorescence. With a focus on Precision Pathology and Spatially Intelligent Biology, SpIntellx leverages unbiased spatial analytics powered by explainable AI to enhance understanding of complex cancer biology, thereby facilitating advancements in drug development, diagnostics, and treatment strategies.

Clairways specializes in smart lung monitoring for pharmaceutical clinical trials. Its wearable device captures key respiratory metrics for individuals with asthma, COPD, CF, or other chronic respiratory diseases.

Trilo Therapeutics is a San Francisco-based biotechnology company focused on developing innovative peptide-drug conjugates (PDCs) to overcome the limitations of traditional antibody-drug conjugates (ADCs). Founded by experienced professionals in the biotech and pharmaceutical industries, Trilo employs a unique approach that utilizes macrocyclic D-amino acid peptides to replace the antibody component in ADCs. This method enhances tumor penetration and reduces toxicity compared to conventional L-amino acid peptide-drug conjugates. Trilo's conjugates are designed to be compatible with clinically validated payloads and radionuclides, offering new therapeutic modalities through a "fast in/fast out" mechanism of action. The company's efforts also extend to discovering novel inhibitors of protein interactions for therapeutic purposes, targeting disease-causing proteins related to cancer, autoimmune disorders, and infectious diseases.

TEGA Therapeutics develops glycoscience-based technologies to treat life-threatening diseases. It focuses on glycan science to enhance delivery of enzyme replacement therapies to the brain for lysosomal storage disorders and on producing recombinant heparan sulfate and heparin. The company aims to overcome the blood-brain barrier to enable treatments for unmet medical needs and is based in La Jolla, California.